Probetex Press Releases
Current (2009-2020)
March, 2020
Probetex, Inc. Provided Anti-Monkey GBM Serum for a Sanofi Study Highlighted at the 59th Annual Meeting of the Society of Toxicology.
March 15-19, 2020 at the Anaheim Convention Center in Anaheim, California.
Abstract Number/Poster Board number: 1984/ P296
Abstract Title: Development of a Model of Immune-Mediated Glomerular Injury in Cynomolgus Monkeys to Study Novel Kidney Safety Biomarkers
Presenting Author: Jean Gautier
Session Title: Kidney
Session Time: 3/17/2020 10:45:00 AM to 3/17/2020 12:30:00 PM
Presentation Location: CC Exhibit Hall.
September, 2018
Probetex, Inc. Provides Anti-thymocyte (Thy1) Serum and CRO Services for a Retrophin Study Highlighted in an Upcoming Presentation at the 15th International Symposium on IgA Nephropathy.
Effect of Sparsentan, a Dual Angiotensin II Type 1 (AT1) and Endothelin Type A (ETA) Receptor Antagonist, in the Rat anti-Thy1 Model of Glomerulonephritis Abstract #: 0054 Location: Ballroom Cabildo Friday, September 28, 2018 4:35 p.m. Announcement
Abstract- Kidney Dis 2018;4:141
September, 2018
Probetex, Inc. is Awarded an NIH Small Business Innovation Research (SBIR) Phase I Grant from the National Institute of Environmental Health Sciences (NIEHS) to Develop 3D Platforms to Model Kidney Cell Biology for In Vitro Toxicity Screening: Dr. Veronique Barnes, MD President of Probetex, Inc. announced that Probetex, Inc. was recently awarded a Phase I SBIR grant from the NIEHS of the National Institutes of Health (NIH) titled “3D Biomimetic Platforms to Model Kidney Cell Biology for In Vitro Toxicity Screening”. The $150,000 grant will aid the company in further developing its technology of 3-dimensional (3D) growth of mouse kidney medullary cells in vitro. Kidney primordial cells (ureteric bud and metanephric mesenchymal cells) reciprocally induce each other to develop into kidney organoids consisting of collecting duct epithelium surrounded by vascular structures. The organoids grown in 3D scaffolds in vitro will be used to assess the toxicity of drugs and environmental chemicals that could have deleterious effects on kidney development and function. The grant was funded by a NIEHS research initiative “Organotypic Culture Models Developed from Experimental Animals for Chemical Toxicity Screening” to develop novel, physiologically-relevant in vitro screening systems to replicate biological interactions and toxicological responses observed in animal tissues and organs. The technology may ultimately provide alternative methods to reduce the use of animals in toxicity testing. Jeffrey L. Barnes, PhD, Chief Science Officer and Director of Research at Probetex will serve as Principal Investigator (NIEHS Award Number R43ES029879).
February, 2018
Probetex Product Used in Landmark Study on Glycoengineering in Autoimmune Disease: Probetex product PTX-001 anti-rat glomeruli (glomerular basement membrane) was used by Robert Anthony and his research team at Massachusetts General Hospital to induce immune-mediated glomerulonephritis to explore the role of glycoconjugates in autoimmune disease. The study published in CELL was widely acclaimed as a significant scientific breakthrough with far-reaching therapeutic potential:
Pagan JD, Kitaoka M, Anthony RM. Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease. Cell. 172(3): 564-577, 2018. Massachusetts General Hospital & Harvard Medical School Read Summary
January, 2018
Probetex Publishes Article on Kidney Progenitor Cell Vasculogenesis in 3D Culture:
Patel M, Velagapudi C, Burns HS, Doss R, Lee, MJ, Mariappan M, Wagner B, Arar M, Barnes VL, Abboud HE, Barnes JL. Mouse metanephric mesenchymal cell-derived angioblasts undergo vasculogenesis in three-dimensional culture. In Press, Am J Pathol 2018.(CMMM-1 and CMUB-1: Mouse Kidney Primordial Cells)
This article describes for the first time kidney primordial mesenchymal cell-derived angioblasts differentiate into capillary-like structures in co-culture with ureteric bud cells or in 3D sea sponge scaffolds in response to PDGF-BB.
Abstact: www.ncbi.nlm.nih.gov/pubmed/29269120
October, 2017
Probetex Modernizes its Logo and Branding:
Probetex is introducing a new corporate logo to complement our ongoing modernization project. The new logo contemporizes multiple triplicate sets of blue, cyan and red dots meant to convey the analytical aspects of contract research. This future-oriented logo is Probetex’s first design change since 2004.
2004-2017 2017- current
September, 2017
Jeffrey L. Barnes Assumes Leadership Role at Probetex, Inc.:
Veronique L. Barnes, MD, President and CFO of Probetex, Inc., a local Biotechnology company announced yesterday that Jeffrey L. Barnes, PhD officially joined the company as Chief Scientific Officer and Executive Director of Research effective September 1, 2017. Probetex, Inc. is a Life Science and Contract Research Organization (CRO) specializing in pathological assessment of kidney and other organ diseases. Probetex currently offers services and products to pharmaceutical companies as well as to numerous biotechnology and academic institutions. Dr. Jeffrey Barnes is an experimental pathologist providing his expertise to Probetex after a successful academic career of more than 30 years with the University of Texas Health Science Center at San Antonio where he was a Professor of Medicine, Division of Nephrology. Dr. Barnes is an internationally known experimental pathologist with over 200 publications in the form of peer-reviewed journal articles, book chapters, reviews and abstracts. He is a highly sought consultant for Pharmaceutical, Biotechnology and Academic institutions. Dr. Barnes will focus his efforts on further developing Probetex as a first class CRO on domestic and international levels. Dr. Barnes Curriculum Vitae
May, 2017
Probetex announces that it will attend and exhibit at the American Society of Nephrology Kidney Week 2017. November 2-4, 2017, Morial Convention Center, New Orleans, LA. Booth #415 see floor plan
See booth banners
November, 2014
Probetex, Inc. is listed as a co-investigating CRO in a recently published article in the American Journal of Pathology:
Riser BL, Najmabadi F, Garchow K, Barnes JL, Peterson DR, Sukowski EJ. Treatment with the matricellular protein CCN3 blocks and/or reverses fibrosis development in obesity with diabetic nephropathy. Am J Pathol 184: 2908–2921, 2014. see Riser et al article.
August 14, 2014
Probetex, Inc. is awarded an SBIR Phase I Grant from the National Institutes of Health (NIGMS) to study kidney progenitor cells in regenerative medicine.
Probetex was awarded a one-year grant to test the efficacy of kidney progenitor cells in cell-based therapy to treat experimental acute renal failure. Metanephric mesenchymal cells, glomerular progenitor and ureteric bud primordial cells will be used in models of acute kidney injury that target specific renal structures. More.....
February, 2012
Probetex publishes an article and cover photo on kidney progenitor cells in 3-dimensional matrices
Velagapudi C, Nilsson R-P, Barnes VL, Arar M, Abboud HE, Barnes JL. Reciprocal induction of simple organogenesis by mouse kidney progenitor cells in three-dimensional co-culture. Am J Pathol 180:819-830, 2012. see article...
American Journal of Pathology, 180:819-830, 2012. (Cover Photo)
August 24, 2009
Probetex, Inc. is Awarded an STTR Phase II Grant from the National Institutes of Health (NIDDK) to commercialize kidney embryonic progenitor cells.
R42DK077436-02 & 3 "Commercialization of Embryonic Kidney Cell Lines"
Probetex was awarded a two-year grant to validate and commercialize three existing kidney embryonic primordial cell lines licensed to Probetex from the University of Texas Health Science Center. The aims are to further characterize the differentiation potential of embryonic mesenchymal and ureteral bud cell lines derived from kidney primordia; To isolate and characterize new embryonic cell lines derived from the nephrogenic zone of embryonic metanephric kidney; and to establish a cell bank of embryonic kidney cell lines created during Phase I.
February, 2009
Probetex, Inc. is listed as a co-investigating biotechnology company in a recently published article in Clinical & Experimental Immunology.
McIntosh LM, Barnes JL, Barnes VL, McDonald JR. Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol 155:295-303, 2009.
March, 2020
Probetex, Inc. Provided Anti-Monkey GBM Serum for a Sanofi Study Highlighted at the 59th Annual Meeting of the Society of Toxicology.
March 15-19, 2020 at the Anaheim Convention Center in Anaheim, California.
Abstract Number/Poster Board number: 1984/ P296
Abstract Title: Development of a Model of Immune-Mediated Glomerular Injury in Cynomolgus Monkeys to Study Novel Kidney Safety Biomarkers
Presenting Author: Jean Gautier
Session Title: Kidney
Session Time: 3/17/2020 10:45:00 AM to 3/17/2020 12:30:00 PM
Presentation Location: CC Exhibit Hall.
September, 2018
Probetex, Inc. Provides Anti-thymocyte (Thy1) Serum and CRO Services for a Retrophin Study Highlighted in an Upcoming Presentation at the 15th International Symposium on IgA Nephropathy.
Effect of Sparsentan, a Dual Angiotensin II Type 1 (AT1) and Endothelin Type A (ETA) Receptor Antagonist, in the Rat anti-Thy1 Model of Glomerulonephritis Abstract #: 0054 Location: Ballroom Cabildo Friday, September 28, 2018 4:35 p.m. Announcement
Abstract- Kidney Dis 2018;4:141
September, 2018
Probetex, Inc. is Awarded an NIH Small Business Innovation Research (SBIR) Phase I Grant from the National Institute of Environmental Health Sciences (NIEHS) to Develop 3D Platforms to Model Kidney Cell Biology for In Vitro Toxicity Screening: Dr. Veronique Barnes, MD President of Probetex, Inc. announced that Probetex, Inc. was recently awarded a Phase I SBIR grant from the NIEHS of the National Institutes of Health (NIH) titled “3D Biomimetic Platforms to Model Kidney Cell Biology for In Vitro Toxicity Screening”. The $150,000 grant will aid the company in further developing its technology of 3-dimensional (3D) growth of mouse kidney medullary cells in vitro. Kidney primordial cells (ureteric bud and metanephric mesenchymal cells) reciprocally induce each other to develop into kidney organoids consisting of collecting duct epithelium surrounded by vascular structures. The organoids grown in 3D scaffolds in vitro will be used to assess the toxicity of drugs and environmental chemicals that could have deleterious effects on kidney development and function. The grant was funded by a NIEHS research initiative “Organotypic Culture Models Developed from Experimental Animals for Chemical Toxicity Screening” to develop novel, physiologically-relevant in vitro screening systems to replicate biological interactions and toxicological responses observed in animal tissues and organs. The technology may ultimately provide alternative methods to reduce the use of animals in toxicity testing. Jeffrey L. Barnes, PhD, Chief Science Officer and Director of Research at Probetex will serve as Principal Investigator (NIEHS Award Number R43ES029879).
February, 2018
Probetex Product Used in Landmark Study on Glycoengineering in Autoimmune Disease: Probetex product PTX-001 anti-rat glomeruli (glomerular basement membrane) was used by Robert Anthony and his research team at Massachusetts General Hospital to induce immune-mediated glomerulonephritis to explore the role of glycoconjugates in autoimmune disease. The study published in CELL was widely acclaimed as a significant scientific breakthrough with far-reaching therapeutic potential:
Pagan JD, Kitaoka M, Anthony RM. Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease. Cell. 172(3): 564-577, 2018. Massachusetts General Hospital & Harvard Medical School Read Summary
- Featured in "Research Highlights" McHugh J. Autoimmunity: Glycoengineering has therapeutic potential. Nat Rev Rheumatol. 14(3):121, 2018.
- Featured in GEN News Highlights (read article)
- Lupus Research Alliance Research Report (read article)
- Paper of the year by The Latest Science (see listing).
- Science News- Science Daily (read article)
January, 2018
Probetex Publishes Article on Kidney Progenitor Cell Vasculogenesis in 3D Culture:
Patel M, Velagapudi C, Burns HS, Doss R, Lee, MJ, Mariappan M, Wagner B, Arar M, Barnes VL, Abboud HE, Barnes JL. Mouse metanephric mesenchymal cell-derived angioblasts undergo vasculogenesis in three-dimensional culture. In Press, Am J Pathol 2018.(CMMM-1 and CMUB-1: Mouse Kidney Primordial Cells)
This article describes for the first time kidney primordial mesenchymal cell-derived angioblasts differentiate into capillary-like structures in co-culture with ureteric bud cells or in 3D sea sponge scaffolds in response to PDGF-BB.
Abstact: www.ncbi.nlm.nih.gov/pubmed/29269120
October, 2017
Probetex Modernizes its Logo and Branding:
Probetex is introducing a new corporate logo to complement our ongoing modernization project. The new logo contemporizes multiple triplicate sets of blue, cyan and red dots meant to convey the analytical aspects of contract research. This future-oriented logo is Probetex’s first design change since 2004.
2004-2017 2017- current
September, 2017
Jeffrey L. Barnes Assumes Leadership Role at Probetex, Inc.:
Veronique L. Barnes, MD, President and CFO of Probetex, Inc., a local Biotechnology company announced yesterday that Jeffrey L. Barnes, PhD officially joined the company as Chief Scientific Officer and Executive Director of Research effective September 1, 2017. Probetex, Inc. is a Life Science and Contract Research Organization (CRO) specializing in pathological assessment of kidney and other organ diseases. Probetex currently offers services and products to pharmaceutical companies as well as to numerous biotechnology and academic institutions. Dr. Jeffrey Barnes is an experimental pathologist providing his expertise to Probetex after a successful academic career of more than 30 years with the University of Texas Health Science Center at San Antonio where he was a Professor of Medicine, Division of Nephrology. Dr. Barnes is an internationally known experimental pathologist with over 200 publications in the form of peer-reviewed journal articles, book chapters, reviews and abstracts. He is a highly sought consultant for Pharmaceutical, Biotechnology and Academic institutions. Dr. Barnes will focus his efforts on further developing Probetex as a first class CRO on domestic and international levels. Dr. Barnes Curriculum Vitae
May, 2017
Probetex announces that it will attend and exhibit at the American Society of Nephrology Kidney Week 2017. November 2-4, 2017, Morial Convention Center, New Orleans, LA. Booth #415 see floor plan
See booth banners
November, 2014
Probetex, Inc. is listed as a co-investigating CRO in a recently published article in the American Journal of Pathology:
Riser BL, Najmabadi F, Garchow K, Barnes JL, Peterson DR, Sukowski EJ. Treatment with the matricellular protein CCN3 blocks and/or reverses fibrosis development in obesity with diabetic nephropathy. Am J Pathol 184: 2908–2921, 2014. see Riser et al article.
August 14, 2014
Probetex, Inc. is awarded an SBIR Phase I Grant from the National Institutes of Health (NIGMS) to study kidney progenitor cells in regenerative medicine.
Probetex was awarded a one-year grant to test the efficacy of kidney progenitor cells in cell-based therapy to treat experimental acute renal failure. Metanephric mesenchymal cells, glomerular progenitor and ureteric bud primordial cells will be used in models of acute kidney injury that target specific renal structures. More.....
February, 2012
Probetex publishes an article and cover photo on kidney progenitor cells in 3-dimensional matrices
Velagapudi C, Nilsson R-P, Barnes VL, Arar M, Abboud HE, Barnes JL. Reciprocal induction of simple organogenesis by mouse kidney progenitor cells in three-dimensional co-culture. Am J Pathol 180:819-830, 2012. see article...
American Journal of Pathology, 180:819-830, 2012. (Cover Photo)
August 24, 2009
Probetex, Inc. is Awarded an STTR Phase II Grant from the National Institutes of Health (NIDDK) to commercialize kidney embryonic progenitor cells.
R42DK077436-02 & 3 "Commercialization of Embryonic Kidney Cell Lines"
Probetex was awarded a two-year grant to validate and commercialize three existing kidney embryonic primordial cell lines licensed to Probetex from the University of Texas Health Science Center. The aims are to further characterize the differentiation potential of embryonic mesenchymal and ureteral bud cell lines derived from kidney primordia; To isolate and characterize new embryonic cell lines derived from the nephrogenic zone of embryonic metanephric kidney; and to establish a cell bank of embryonic kidney cell lines created during Phase I.
February, 2009
Probetex, Inc. is listed as a co-investigating biotechnology company in a recently published article in Clinical & Experimental Immunology.
McIntosh LM, Barnes JL, Barnes VL, McDonald JR. Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol 155:295-303, 2009.